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Abstract
Background: Since the 1980s, Stenotrophomonas maltophilia has emerged as an important pathogen associated with significant
mortality in pneumonia and bacteremia of severely immunocompromised, hospitalized patients. The drug of choice in S maltophilia
infections is sulfamethoxazole-trimethoprim (SMX/TMP); SMX/TMP resistance is a serious concern in clinical practice. The aim of
this study was to assess the prevalence of S maltophilia in lower respiratory tract (LRTI) samples at a tertiary-care university
hospital.
Methods: This retrospective cohort study was carried out using microbiological data collected between January 2008 and
December 2017. Routine antimicrobial susceptibility testing was performed for SMX/TMP and levofloxacin; in case of resistance,
susceptibility testing for additional antibiotics (tigecycline, amikacin, and colistin) was also performed.
Results: A total of 579 individual S maltophilia isolates were identified (2008-2012: n¼ 160, 2013-2017: n¼ 419; P¼ .0008). In all,
78.46% of patients were younger than 5 or older than 50 years of age and had recent trauma, surgery, or underlying conditions
(malignancies, respiratory distress syndrome, congenital disorders, and cystic fibrosis). In 28.16% of samples, more than 1
pathogen was identified, and 5.35% of coisolated pathogens were multidrug resistant (MDR). In all, 12.1% of isolates were SMX/
TMP-resistant (2008-2012: 6.12%, 2013-2017: 18.06%; P ¼ .034), while 8.99% were resistant to levofloxacin (2008-2012: 7.86%,
2013-2017: 10.12%; P > .05). SMX/TMP resistance was detected more frequently in samples originating from inpatients (n ¼ 2.50
+ 2.39 vs n ¼ 11.50 + 3.76; P ¼ .0002).
Conclusions: In all, 5.87% of isolates were extensively drug resistant (XDR), that is, in addition to SMX/TMP, they were resistant
to levofloxacin, amikacin, colistin, and tigecycline. The results of our study correspond to the findings in the literature.
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Introduction
Stenotrophomonas maltophilia is a nonfermenting Gram-
negative rod that is ubiquitous in nature (predominantly occur-
ring in aquatic environments and on plants)1. Biochemically, it is
catalase positive and oxidase negative, and it produces acid from
maltose (hence the name “maltophilia”).2,3 Due to its charged
cell wall surface and biofilm production, it may attach to and
survive on abiotic surfaces in clinical settings (eg, central venous
catheters, disinfectant and hand-washing solutions, solutions for
hemodialysis, endoscopes, inspiration/expiration circuits of
ventilators, nebulizers, tap water, and showerheads).1,4-7 This
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pathogen is frequently responsible for nosocomial outbreaks,
especially in intensive care units (ICUs).6,8,9 Before the 1980s,
there have been seldom reports of the isolation of this micro-
organism in the context of human infections10; however, after
the 1980s, the prevalence of nosocomial infections associated
with S maltophilia has increased rapidly.11 On the one hand,
S maltophilia is a pathogen of low virulence and limited inva-
siveness; therefore, bypassing the natural defenses of the body is
crucial for the development of any pathologies.1,4,10-12 Advance-
ments in medical interventions (complex surgeries, chemother-
apy of advanced malignancies, immunosuppressive therapy for
organ transplantation, or autoimmune disorders) have also
resulted in the increase in the number of patients at risk.1,4,10-
12 Nonetheless, advancements in the identification methods in
clinical microbiology laboratories (eg, polymerase chain reac-
tion, mass spectrometry, and sequencing) have allowed for the
more precise identification of this pathogen.13-15 To complicate
things even further, the prevalence of community-acquired
S maltophilia infections (presumably due to the increase in the
number of immunocompromised/debilitated patients in outpati-
ent care settings) has also increased since the 2000s.16
The main clinical manifestations of S maltophilia infections
include nosocomial lower respiratory tract infections (LRTIs;
namely, tracheobronchitis/pneumonia, usually associated with
mechanical ventilation) and bacteremia. Nevertheless, other
manifestations, for example, wound/soft tissue infections (ie,
ecthyma gangrenosum), cellulitis, mastoiditis, meningitis, peri-
tonitis, bone and joint infections, urinary tract infections, conjunc-
tivitis, and otitis media have also been described.4,9-11 These
infections usually occur in severely debilitated, immunosup-
pressed individuals, in addition to patients with a chronic illness
or a developmental abnormality affecting a specific organ sys-
tem.4,9-11,17-19 Stenotrophomonas maltophilia represents the
fourth most common pathogen among nonfermenting gram-
negative bacteria (following Pseudomonas aeruginosa, Acineto-
bacter spp, and Burkholderia cepacia complex), with a reported
incidence of 7.1 to 37.7 cases/10 000 discharges (regarding noso-
comial infections)20. Stenotrophomonas maltophilia infections
are associated with a high crude mortality of 25% to 75% in case
of pneumonia and 20% to 60% in case of bacteremia.3 The mor-
tality rate increases sharply if the patients receive inappropriate
antimicrobial therapy (which mainly occurs empirically)3,4,9-11.
Stenotrophomonas maltophilia may colonize the respiratory
tract and persist in the sputum of these patients for a long period
of time; therefore, it may be difficult to ascertain the clinical
significance of a positive culture result from the microbiology
laboratory.21,22 However, previously verified colonization is one
of the main risk factors for manifestation of S maltophilia LRTI;
thus, culture positivity for this microorganism does pertain clini-
cally useful information.6,21,22 While some reports suggest that
S maltophilia LRTIs are characterized by the lack of acute
inflammatory response, Di Bonaventura et al found an pro-
nounced inflammatory response (increased expression of IL-8
and TNF-a) in murine airway epithelial cells and macrophages,
which may contribute to airway inflammation in vivo.23,24 His-
tologically, S maltophilia LRTIs are frequently characterized by
focal lung necrosis and lung hemorrhage, while pleural effusions
and cavitations are rarely observed.20 As many S maltophilia
infections are polymicrobial, clinicians should be extremely cau-
tious when interpreting radiological findings (especially in
patients with cancer), as several copathogens (eg, Pseudomonas
spp, Acinetobacter spp, Nocardia spp, Staphylococcus aureus,
and opportunistic fungi) may be present simultaneously.1,4,10-12
In severely immunosuppressed patients, fatal hemorrhagic pneu-
monia may occur, which is the fulminant course of the infec-
tion.10-12 In addition, S maltophilia is a well-known colonizer
and pathogen in patients with cystic fibrosis (CF); it has been
described that the colonization/infection rate (especially in 105-
106 CFU) correlates well with disease progression and loss of
lung function.25,26 Air-borne transmission of this microorganism
from the cough (aerosol) of patients with CF have also been
described.25,26
The therapeutic options regarding S maltophilia infections
are very limited, owing to the intrinsic resistance of this patho-
gen to several classes of antibiotics: b-lactam antibiotics (most
notably carbapenems) are hydrolyzed by zinc-dependent, chro-
mosomally mediated b-lactamases (namely, L1 and L2), ami-
noglycosides (acetyl-transferases and temperature-dependent
changes in the lipopolysaccharide), while a plethora of other
drugs may be affected by the overexpression of energy-
dependent efflux pumps.4,7,9-11,20 Currently, the therapy of
choice in these infections is a high-dose sulfamethoxazole/tri-
methoprim (SMX/TMP; cotrimoxazole)1,9-11. Although a
recent publication by Ko et al has reported that fluoroquino-
lones (a popular alternative to cotrimoxazole) are equally
effective in the therapy of these infections27, SMX/TMP resis-
tance (among other things, as drug allergies may also be pres-
ent) is a serious therapeutic challenge for clinicians. Due to the
proclivity of this microorganism to become multidrug resistant
(MDR) and extensively drug resistant (XDR), it has been listed
by the World Health Organization as one of the most concern-
ing multidrug resistant organisms worldwide.28 Apart from
SMX/TMP and fluoroquinolones, other drugs that may be con-
sidered for therapy (and several case reports are available in
successfully curing patients) are the tetracyclines (doxycycline,
minocycline, and tigecycline), ticarcillin/clavulanate, ceftazi-
dime, colistin, and chloramphenicol4,7,9-11,20.
Despite the abundance of global surveillance studies pub-
lished, there are only few reports assessing the microbiological
and clinical significance of S maltophilia in LRTIs, as the
majority of studies have focused on the isolation of MDR
Pseudomonas spp and Acinetobacter spp. The aim of this study
was to assess the prevalence of S maltophilia in respiratory
tract specimens at a tertiary-care hospital in Hungary retrospec-
tively, during a 10-year study period (2008-2017).
Materials and Methods
Characteristics of the Study and the Clinical Center
This study was performed on the basis of retrospectively col-
lected microbiological data regarding a 10-year time period on
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January 1, 2008, to December 31, 2017. Our institute is the
dedicated microbiological diagnostic laboratory of a 1820-bed
tertiary-care teaching hospital in Szeged (Hungary), which is
responsible for the medical care of >400 000 patients in the
southern region of Hungary. Data were collected by an elec-
tronic search of the Institutional laboratory information system
records for the designated time period, which was conducted by
the authors. Isolates were considered separate if their isolation
happened >14 days apart, or S maltophilia isolates with differ-
ent antibiotic susceptibility results were detected from the same
patient. Polymicrobial infection was defined by the isolation of
more than 1 organism in a single sample.29 As a part of this
study, data on the affected patients were also collected, which
was limited to demographic characteristics (age, sex, and inpa-
tient/outpatient status) and the indication for sample submis-
sion. The relevant data were collected if S maltophilia was
isolated in significant colony count from the samples of the
abovementioned patients. The study was deemed exempt from
ethics review by the institutional review board, and informed
consent was not required as data anonymity was maintained.
Processing of Microbiological Samples, Identification,
and Susceptibility Testing
Respiratory sampling from patients was performed in line with
current recommendations with international guidelines, respec-
tive to each individual sample type. The processing of respira-
tory tract samples was based on current international guidelines
of routine clinical bacteriology; culture plates were incubated
at 37C for 24 to 48 hours, aerobically. For bacterial identifi-
cation, classical phenotypic methods and VITEK 2 Compact
ID/AST (bioMe´rieux, Marcy-l’E´toile, France) were used
between 2008 and 2012; however, starting with 2013, matrix-
assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS; Bruker Daltonik GmbH, Ger-
many) was introduced to the diagnostic workflow of our
laboratory. Sample preparation methods and technical specifi-
cations for MALDI-TOF MS measurements are described else-
where.30 Susceptibility testing for S maltophilia isolates was
performed for SMX/TMP and levofloxacin routinely; if SMX/
TMP resistance was detected, supplementary antibiotics (tige-
cycline, amikacin, and colistin) were also tested. The suscept-
ibility testing methods utilized and the interpretative criteria
were described elsewhere in detail.29
Statistical Analyses
Data for analysis were collected from the MedBakter labora-
tory information system, while the management of data and the
preparation of data for statistical analyses were performed
using Microsoft Excel 2013 (Microsoft Corp, Redmond,
Washington). Statistical analyses were performed with SPSS
software version 24 (IBM SPSS Statistics for Windows 24.0;
IBM Corp Armonk, New York). The normality of variables
was tested using Shapiro-Wilk tests. P values <.05 were con-
sidered statistically significant.
Results
A total of 579 S maltophilia isolates were identified (57.9 +
31.0/year, highest in 2015, lowest in 2008) from various
respiratory samples between 2008 and 2017. The number of
isolates between 2008 and 2012 was n ¼ 160 (32.0 + 5.33/
year, range: 24-38), while for 2013 to 2017 this number was n
¼ 419 (83.8 + 21.53/year, range: 55-111). A sizable (P ¼
.0008) increase was observed in the detection of S maltophilia
in the second part of the study period (2013-2017). The affected
patients presented with a pronounced male dominance (female-
to-male ratio: 0.69; 63.84% male); the median age of the
affected patients was 55 years (range: 0-96 years), both in the
inpatient and outpatient groups. The age distribution of patients
was as follows: 16.03% 0 to 5 years, 3.84% 6 to 17 years,
6.51% 18 to 35 years, 11.20% 36 to 50 years, 26.24% 51 to
65 years, and 36.19% of patients were older than 65 years.
Tracheal aspirates were the most common samples type
(65.28%), followed by sputum samples (17.20%), bronchoal-
veolar lavage (BAL; 16.82%, including and bronchoscopic
BAL and MiniBAL), in addition to samples attained through
pleural and pericardial puncture (0.35% each). Indications for
the submission of the abovementioned positive samples
included septicemia (19.17%), hematological malignancies
(predominantly acute myeloid leukemia) and solid tumors
(lung, stomach, and colon cancer; 16.23%), recent trauma,
burns or invasive surgery (13.47%), congetinal disorders or
preterm delivery (12.78%), pneumonia, pleuritis or acute
respiratory distress syndrome (11.07%), cardiovascular ill-
nesses (10.89%), cystic fibrosis (6.91%), meningitis (5.54%),
or other reasons (3.94%). The largest amount of isolates origi-
nated from the intensive care units (which has 3 subsections,
namely, cardiology–hematology, surgery, and traumatology;
47.49%), department of internal medicine (27.29%), depart-
ment of pediatrics and neonatology (9.86%), department of
otorhinolaryngology, head and neck surgery (8.11%), depart-
ment of oncology (5.78%), and other affiliated institutions
(1.47%). At the time of isolation, 24.89% of affected patients
were treated as outpatients; the number of isolates from out-
patient samples was significantly higher in the second half of
the study period (n ¼ 40 vs n ¼ 103; P < .04).
In 71.84% of relevant respiratory samples, S maltophilia
was the only isolated pathogen, whereas in 28.16%, more than
1 (2 in 18.13%, 3 in 6.05%, 4 in 2.76%, and 5 or more in 1.21%)
different species could be isolated (Table 1). Other nonfer-
menting Gram-negative and Candida species were the most
frequent species coisolated. Pseudomonas aeruginosa (in 57
cases) and C albicans (in 54 cases) were the most frequent
coisolates; 5.35% of coisolated pathogens were MDR (includ-
ing MDR P aeruginosa, methicillin-resistant S aureus
[MRSA], and extended-spectrum b-lactamase-producing
[ESBL] Enterobacteriaceae).
During the 10-year period, almost 88% (87.90%) of respira-
tory S maltophilia were susceptible to SMX/TMP, while
levofloxacin susceptibility (Minimum Inhibitory Concentra-
tion [MIC] range: 0.5-64 mg/L) was shown to be somewhat
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higher (91.01%). This left 12.1% of isolates (2008-2012:
6.12%; 2013-2017: 18.06%; P ¼ .034) resistant to SMX/TMP
and 8.99% of isolates (2008-2012: 7.86%; 2013-2017: 10.12%;
P > .05) resistant to levofloxacin, respectively. Of the SMX/
TMP-resistant S maltophilia strains, 71.42% was also resistant
to amikacin (MIC range: 1-32 mg/L), 10.20% for tigecycline
(MIC range: 1-32 mg/L), and 8.57% for colistin (MIC range:
0.25-256 mg/L). It is worth noting that in 5.87% of isolates,
resistance to SMX/TMP, levofloxacin, amikacin, tigecycline,
and colistin was present simultaneously; therefore, these iso-
lates should be considered XDR strains. The SMX/TMP resis-
tance was detected more frequently in samples originating from
inpatients (n ¼ 2.50 + 2.39 vs n ¼ 11.50 + 3.76; P ¼ .0002),
while a numerical but not statistical tendency was observed for
levofloxacin resistance (n ¼ 4.49 + 0.23 vs n ¼ 5.86 + 0.91;
P ¼ .078).
Discussion
The amount of specific studies regarding the prevalence and
resistance trends of S maltophilia isolates in LRTI samples is
very limited, the available literature concerning this topic is
summarized by the authors in Table 2. Stenotrophomonas mal-
tophilia LRTIs are thought to be infrequent, but their clinical
relevance is increasing in the era of surgical interventions and
heavily immunosuppressed patients.1-4,9-11,16-22 The presence
of obstruction in the lungs creates advantageous conditions for
several opportunistic pathogens to cause infections, including
S maltophilia, in addition obstruction has been shown to be an
independent risk factor for a poor outcome.3 In line with the
findings of other studies, we have demonstrated that most of the
affected patients were very young or older than 50 years of age
(78.46% of patients in the present study), with an observed
male dominance in the patient population. A possible explana-
tion for this phenomenon is that males are more prone to con-
tract S maltophilia, due to their activities in the outdoors/
aquatic environments.3 Based on our results, we have noted
an increase in the isolation rate of S maltophilia from LRTI
samples, in addition to an increase in its prevalence in out-
patient settings. The introduction of MALDI-TOF MS in our
institute may explain the increase in the detection of these
species; additionally, carbapenem prescription levels (both in
the region and in Hungary overall) have increased dramatically
(mainly due to the emergence of ESBL-positive strains) which
may also have resulted in a more pronounced selection pressure
for S maltophilia isolates.49
The local levels of SMX/TMP resistance were similar to
those found in the global literature (Western Hemisphere:
2%-10%; however, some outliers with higher resistance levels
[eg, Spain: 27%; Turkey 10%-15%] in Europe and Asia [Tai-
wan: > 25%; China: 30%-48%]) but somewhat higher than the
European average.7 In a similar study recently published by
Gajda´cs et al in the same geographical region, 16.0% of isolates
from bacteremia were resistant to SMX/TMP, and of these
resistant strains, 32.7% were also resistant to levofloxacin,
tigecycline, and colistin (thus, 5.2% overall were XDR iso-
lates).29 In contrast, during our current study regarding respira-
tory isolates, it was found that the levels of SMX/TMP and
LEV resistance were lower (12.1% and 8.99%, respectively),
while the ratio of XDR isolates was higher, recorded at 5.87%.
It must be noted that in patients with malignant neoplasms, ICU
patients, and patients with CF, resistance levels may be even
higher (20%-80%).4 The matter of SMX/TMP resistance is
complex, as there is no definite consensus or guideline on the
susceptibility testing and interpretation (breakpoints) for S mal-
tophilia for several antibiotics, which may lead to confusion
when interpreting published clinical data. Institutions must
establish therapeutic protocols for these cases based on local
resistance trends and international guidelines. In addition, more
studies are needed to assess the relevance of various combina-
tion therapies in a controlled clinical setting.50
Several limitations of this study should be acknowledged.
First, due to the inability to access the medical records of the
individual affected patients, the presence and nature of symp-
toms of the patients were unknown. Additionally, the correla-
tion between the presence/absence of all relevant risk factors
and S maltophilia isolation from the respiratory tract could not
be assessed. There is also a risk of selection/referral bias, as
studies describing the prevalence of infectious diseases and
resistance trends are mainly tertiary-care centers, which gener-
ally correspond to patients with more severe conditions or
underlying illnesses, compared to community-based settings29.
In this present study, we observed the increasing prevalence
of S maltophilia from respiratory tract specimens; the increase
Table 1. Pathogens Coisolated With Stenotrophomonas Maltophilia in
Respiratory Samples, 2008-2017.
Coisolates in Relevant Respiratory Samples Frequency, n
Pseudomonas aeruginosa 57
Candida albicans 54
Candida glabrata 23
Klebsiella pneumoniae (including ESBL producers) 20
Staphylococcus aureus (including MRSA) 20
Acinetobacter baumannii 12
Enterobacter cloacae (including ESBL producers) 7
Escherichia coli (including ESBL producers) 6
Candida tropicalis 4
Serratia marcescens 4
Proteus vulgaris 4
Candida krusei 3
Aspergillus fumigatus 3
Escherichia faecium 3
Morganella morganii 3
Acinetobacter niger 2
Candida inconspicua 2
Citrobacter freundii 2
Citrobacter freundii 2
Klebsiella oxytoca 2
Enterobacter cloacae 1
Enterobacter kobei 1
Hafnia alvei 1
Abbreviations: ESBL, extended-spectrum b-lactamase MRSA, methicillin-
resistant Staphylococcus aureus.
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in prevalence may be due to the developments in diagnostic
technologies in microbiology laboratories; however, there have
been reports that isolation of S maltophilia increases propor-
tionally with the utilization rate of carbapenem antibiotics
(which provides selection pressure). Due to the increasing pre-
valence of extended-spectrum b-lactamase-producing gut bac-
teria in severe infections in Hungary, this observation
correlates with the increased administration of carbapenems.
The key points of the present study are the reporting of resis-
tance trends of S maltophilia in the Central Eastern part of
Europe, from where only few reports were published thus far;
while the ratio of resistant strains to SMX/TMP and LEV
(10.12% and 8.99%, respectively) is not outliers from the data
found in the international literature, more than 1 of 20 of these
respiratory isolates were representative of the XDR phenotype.
For severely debilitated, immunocompromised patients, this
corresponds to a very severe therapeutic conundrum, with little
or no antimicrobial options left to treat them.1,29 Both in the
literature and based on our own results, S maltophilia was
isolated with another significant pathogen. Therapeutically,
this may bring forth additional challenges, especially if the
mentioned copathogen is also resistant to several antibiotics
(eg, ESBL Enterobacteriaceae, carbapenem-resistant Pseudo-
monas and Acinetobacter, and MRSA).51-53 The use of inhala-
tional/aerosolized antibiotics may have an important role in the
therapy of these LRTI infections; their use is gaining increasing
attention, in addition to combinational antibiotic therapy.
Authors’ Note
M.G. conceived and designed the study. E.U. was the senior micro-
biologist and performed the identification of the bacterial isolates
during the study period. M.G. and E.U. performed data collection and
analysis, wrote, and revised the full article.
Acknowledgments
The authors would like to thank Tu¨nde Dea´k and Erika Karasz for the
excellent laboratory assistance during the routine diagnostic work.
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest
with respect to the research, authorship, and/or publication of this
article: M.G. was supported by the National Youth Excellence Scho-
larship [Grant Number NTP-NTFO¨-18-C-0225] and the ESCMID
Mentorship and Observership Programme.
Funding
The author(s) received no financial support for the research, author-
ship, and/or publication of this article.
ORCID iD
Ma´rio´ Gajda´cs https://orcid.org/0000-0003-1270-0365
References
1. Adegoke AA, Stenstro¨m TA, Okoh AI. Stenotrophomonas mal-
tophilia as an emerging ubiquitous pathogen: looking beyond
contemporary antibiotic therapy. Front Microbiol. 2017;8:2276.
2. Carmody LA, Spilker T, LiPuma JJ. Reassessment of Stenotro-
phomonas maltophilia phenotype. J Clin Microbiol. 2011;49(3):
1101-1103.
3. Singhal L, Kaur P, Gautam V.Stenotrophomonas maltophilia:
from trivial to grievous. Indian J Med Microbiol. 2017;35(4):
469-479.
4. Brooke JS. Stenotrophomonas maltophilia: an emerging global
opportunistic pathogen. Clin Microbiol Rev. 2012;25(1):2-41.
5. Cervia JS, Ortolano GA, Canonica FP. Hospital tap water as a
source of Stenotrophomonas maltophilia infection. Clin Infect
Dis. 2008;46(9):1485-1487.
6. Looney WJ. Role of Stenotrophomonas maltophilia in hospital-
acquired infection. Br. J. Biomed Sci. 2005;62(3):145-154.
7. Brooke JS. New strategies against Stenotrophomonas maltophilia:
a serious worldwide intrinsically drug-resistant opportunistic
pathogen. Expert Rev Anti Infect Ther. 2014;12(1):1-4.
8. Gulcan H, Kuzucu C, Durmaz R. Nosocomial Stenotrophomonas
maltophilia cross-infection: three cases in newborns. Am J Infect
Control. 2004;32(6):365-368.
9. Rajkumari N, Mathur P, Gupta AK, Sharma K, Misra M.C. Epi-
demiology and outcomes of Stenotrophomonas maltophilia and
Burkholderia cepacia infections among trauma patients of India: a
five year experience. J Infect Prev. 2015;16(3):103-110.
10. Denton M, Kerr KG. Microbiological and clinical aspects of
infection associated with Stenotrophomonas maltophilia. Clin.
Microbiol. Rev. 1998;11(1):57-80.
11. Gilardi GL. Pseudomonas maltophilia infections in man. Am J
Clin Pathol. 1969;51(1):58-61.
12. Wang Y, He T, Shen Z, Wu C. Antimicrobial resistance in Steno-
trophomonas spp. Microbiol Spectr. 2018;6(1):1-14.
13. Schaumann R, Knoop N, Genzel GH, et al. Discrimination of enter-
obacteriaceae and non-fermenting gram negative bacilli by MALDI-
TOF mass spectrometry. Open Microbiol J. 2013;7:118-122.
14. Steensels D, Verhaegen J, Lagrou K. Matrix-assisted laser deso-
rption ionization-time of flight mass spectrometry for the identi-
fication of bacteria and yeasts in a clinical microbiological
laboratory: a review. Acta Clin Belg. 2011;66(4):267-273.
15. Gautam V, Sharma M, Singhal L, et al. MALDI-TOF mass spec-
trometry: An emerging tool for unequivocal identification of non-
fermenting Gram-negative bacilli. Indian J Med Res. 2017;
145(5):665-672.
16. Falagas M.E, Kastoris AC, Vouloumanou EK, Dimopoulos G.
Community-acquired stenotrophomonas maltophilia infections:
a systematic review. Eur J Clin Microbiol Infect Dis. 2009;
28(7):719-730.
17. Falagas ME, Kastoris AC, Vouloumanou EK, Rafailidis PI,
Kapaskelis AM, Dimopoulos G. Attributable mortality of Steno-
trophomonas maltophilia infections: a systematic review of the
literature. Future Microbiol. 2009;4(9):1103-1109.
18. del Toro MD, Rodrı´guez-Bano J, Herrero M, et al. Clinical epi-
demiology of Stenotrophomonas maltophilia colonization and
infection: a multicenter study. Medicine (Baltimore). 2002;
81(3):228-239.
19. Al-Anazi KA, Al-Jasser AM. Infections caused by Stenotropho-
monas maltophilia in recipients of hematopoietic stem cell trans-
plantation. Front Oncol. 2014;4:232.
Gajda´cs and Urba´n 7
20. Gales A.C, Jones RN, Forward KR, Lin˜ares J, Sader HS, Verhoef
J. Emerging importance of multidrug-resistant Acinetobacter spe-
cies and Stenotrophomonas maltophilia as pathogens in seriously
ill patients: geographic patterns, epidemiological features, and
trends in the SENTRY antimicrobial surveillance program
(1997-1999). Clin Infect Dis. 2001;32(suppl 2):S104-113.
21. Millar FA, Simmonds NJ, Hodson ME. Trends in pathogens colo-
nising the respiratory tract of adult patients with cystic fibrosis,
1985-2005. J Cyst Fibros. 2009;8(6):386-391.
22. Bostanghadiri N, Ghalavand Z, Fallah F. Characterization of phe-
notypic and genotypic diversity of Stenotrophomonas maltophilia
strains isolated from selected hospitals in Iran. Front Microbiol.
2019;10:1191.
23. Di Bonaventura G, Pompilio A, Zappacosta R, et al. Role of
excessive inflammatory response to Stenotrophomonas maltophi-
lia lung infection in DBA/2 mice and implications for cystic
fibrosis. Infect Immun. 2010;78(6):2466-2476.
24. Pompilio A, Ciavardelli D, Crocetta V, et al. Stenotrophomonas
maltophilia virulence and specific variations in trace elements
during acute lung infection: implications in cystic fibrosis. PLoS
One. 2014;9(2):e88769.
25. Berdah L, Taytard J, Leyronnas S, Clement A, Boelle PY, Corvol
H.Stenotrophomonas maltophilia: a marker of lung disease sever-
ity. Pediatr Pulmonol. 2018;53(4):426-430.
26. Barsky EE, Williams KA, Priebe GP, Sawicki GS. Incident Ste-
notrophomonas maltophilia infection and lung function decline in
cystic fibrosis. Pediatr. Pulmonol. 2017;52(10):1276-1282.
27. Ko JH, Kang CI, Cornejo-Jua´rez P, et al. Fluoroquinolones versus
trimethoprim-sulfamethoxazole for the treatment of Stenotropho-
monas maltophilia infections: a systematic review and meta-anal-
ysis. Clin. Microbiol. Infect. 2019;25(5):546-554.
28. Gajda´cs M. The concept of an ideal antibiotic: implications for
drug design. Molecules. 2019;24(5):E892.
29. Gajda´cs M, Urba´n E. Epidemiological trends and resistance asso-
ciated with Stenotrophomonas maltophilia bacteremia: a 10-year
retrospective cohort study in a tertiary-care hospital in Hungary.
Diseases. 2019;7(2):E41.
30. Gajda´cs M, Spengler G, Urba´n E. Identification and antimicrobial
susceptibility testing of anaerobic bacteria: Rubik’s cube of clin-
ical microbiology? Antibiotics. 2017;6(4):E25.
31. Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K. A
changing pattern of susceptibility of Xanthomonas maltophilia
to antimicrobial agents: implications for therapy. Antimicrob
Agents Chemother. 1994;38(3):624-627.
32. Gopalakrishnan R, Hawley HB, Czachor JS, Markert RJ,
Bernstein JM. Stenotrophomonas maltophilia infection and
colonization in the intensive care units of two community hospi-
tals: a study of 143 patients. Heart Lung. 1999;28(2):134-141.
33. Aisenberg G, Rolston KV, Dickey BF, Kontoyiannis DP, Raad II,
Safdar A. Stenotrophomonas maltophilia pneumonia in cancer
patients without traditional risk factors for infection, 1997-2004.
Eur J Clin Microbiol Infect Dis. 2007;26(1):13-20.
34. Sader HS, Jones RN, Gales AC, Silva JB, Pignatari AC. SENTRY
antimicrobial surveillance program report: latin American and
Brazilian results for 1997 through 2001. Braz J Infect Dis.
2004;8(1):25-79.
35. Gu¨lmez D, Hasc¸elik G. Stenotrophomonas maltophilia: antimi-
crobial resistance and molecular typing of an emerging pathogen
in a Turkish university hospital. Clin Microbiol Infect. 2005;
11(11):880-886.
36. Tan CK, Liaw SJ, Yu CJ, Teng LJ, Hsueh PR. Extensively drug-
resistant Stenotrophomonas maltophilia in a tertiary care hospital
in Taiwan: microbiologic characteristics, clinical features, and
outcomes. Diagn Microbiol Infect. Dis. 2008;60(2):205-210.
37. Naeem T, Absar M, Somily AM. Antibiotic resistance among
clinical isolates of Stenotrophomonas maltophilia at a teaching
hospital in Riyadh, Saudi Arabia. J Ayub Med Coll Abbottabad.
2012;24(2):30-33.
38. Saugel B, Eschermann K, Hoffmann R, et al. Stenotrophomonas
maltophilia in the respiratory tract of medical intensive care unit
patients. Eur J Clin Microbiol Infect Dis. 2012;31(7):1419-1428.
39. Flores-Trevin˜o S, Gutie´rrez-Ferman JL, Morfı´n-Otero R, et al.
Stenotrophomonas maltophilia in Mexico: antimicrobial resis-
tance, biofilm formation and clonal diversity. J Med Microbiol.
2014;63(pt 11):1524-1530.
40. Sun E, Liang G, Wang L, et al. Antimicrobial susceptibility of
hospital acquired Stenotrophomonas maltophilia isolate biofilms.
Braz J Infect Dis. 2016;20(4):365-373.
41. Gokhan Gozel M, Celik C, Elaldi N. Stenotrophomonas malto-
philia infections in adults: primary bacteremia and pneumonia.
Jundishapur J Microbiol. 2015;8(8):e23569.
42. Rodrigues LS, Gioia TSRD, Rossi F. Stenotrophomonas malto-
philia: resisteˆncia emergente ao SMX-TMP em isolados brasi-
leiros. uma realidade? J Brasileiro de Patologia e Med Lab.
2011;47:511-517.
43. Juha´sz E, Krizsa´n G, Lengyel G, Gro´sz G, Pongra´cz J, Kristo´f K.
Infection and colonization by Stenotrophomonas maltophilia:
antimicrobial susceptibility and clinical background of strains
isolated at a tertiary care centre in Hungary. Ann Clin Microbio
Antimicrob. 2014;13:333.
44. Jia W, Wang J, Xu H, Li G. Resistance of Stenotrophomonas
maltophilia to fluoroquinolones: prevalence in a university hos-
pital and possible mechanisms. Int J Environ Res Public Health.
2015;12(5):5177-5195.
45. Rutter WC, Burgess DR, Burgess DS. Increasing incidence of
multidrug resistance among cystic fibrosis respiratory bacterial
isolates. Microb. Drug Resist. 2017;23(1):51-55.
46. Chawla K, Vishwanath S, Gupta A. Stenotrophomonas maltophi-
lia in lower respiratory tract infections. J Clin Diagn Res. 2014;
8(12):DC20-DC22.
47. Madi H, Lukic´ J, Vasiljevic´ Z, et al. Genotypic and phenotypic
characterization of Stenotrophomonas maltophilia strains from a
pediatric tertiary care hospital in Serbia. Plos One. 2016;11(10):
e0165660.
48. Nayyar C, Thakur P, Tak V, Saigal K. Stenotrophomonas mal-
tophilia: an emerging pathogen in paediatric population. J Clin
Diagn Res. 2017;11(1):DC08-DC11.
49. Benk}o R, Matuz M, Hajdu´ E, et al . [Antibiotic use in the Hun-
garian hospitals in the last two decades (1996-2015)]. Orv Hetil.
2016;157(46):1839-1846.
50. Araoka H, Baba M, Okada C, Abe M, Kimura M, Yoneyama A.
Evaluation of trimethoprim-sulfamethoxazole based combination
8 Health Services Research and Managerial Epidemiology
therapy against Stenotrophomonas maltophilia: in vitro effects and
clinical efficacy in cancer patients. Int J Infect Dis. 2017;58:18-21.
51. As¸ik G, C¸iftc¸i IH, Aktepe OC, C¸etinkaya Z, Altindis¸ M. In vitro
activity of fosfomycin against extended spectrum-b-lactamase
(ESBL) producing Escherichia coli and Klebsiella pneumoniae
strains. Turk J Immunol. 2008;13(1):1-4.
52. Gajda´cs M. The continuing threat of methicillin-resistant Staphy-
lococcus aureus. Antibiotics. 2019;8(2):E52.
53. Codjoe FS, Donkor ES. Carbapenem Resistance: a review. Med
Sci (Basel). 2017;6(1):1.
Author Biographies
Ma´rio´ Gajda´cs graduated as a Doctor of Pharmacy (PharmD) at the
University of Szeged in 2016 and as a medical translator-interpreter
in 2018. He received his PhD from the Experimental chemother-
apy/Medical microbiology program of the Faculty of Medicine,
University of Szeged. He is currently in the process of becoming
a specialized pharmacist in “Pharmacology, pharmacotherapy”
and an assistant professor at the Department of Pharmacody-
namics and Biopharmacy, Faculty of Medicine, University of
Szeged.
Edit Urba´n graduated as a Doctor of Pharmacy (PharmD) at the
University of Szeged in 1989, as a specialist in laboratory medicine
in 1996, and as a clinical microbiologist in 1999. She received her PhD
in Clinical microbiology in 2002 from the Faculty of Medicine, Uni-
versity of Szeged. She is currently a full professor at the University of
Szeged.
Gajda´cs and Urba´n 9
